Loading...
XLONMSYS
Market cap1mUSD
Dec 24, Last price  
0.78GBP
1D
-6.06%
Jan 2017
-77.04%
IPO
-98.15%
Name

Microsaic Systems PLC

Chart & Performance

D1W1MN
XLON:MSYS chart
P/E
—
P/S
282.24
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
81.33%
Rev. gr., 5y
-3.18%
Revenues
492k
-68.62%
711,000622,000396,000197,000268,000606,2811,165,2351,143,213782,813851,180342,514578,258872,125198,258906,8761,567,697492,000
Net income
-3m
L+13.47%
-936,000-1,070,000-1,157,000-807,000-1,898,000-1,867,069-2,285,158-3,004,120-3,524,845-3,101,985-2,643,003-2,763,961-2,781,087-2,372,658-3,128,581-2,288,709-2,597,000
CFO
-1m
L-50.41%
-945,000-898,000-1,006,000-535,000-2,033,000-1,373,092-2,280,814-2,803,076-3,822,868-2,795,922-2,450,924-2,715,676-2,536,086-2,029,504-1,603,046-2,133,332-1,058,000
Earnings
Jan 13, 2025

Profile

Microsaic Systems plc engages in the research, development, and commercialization of miniaturised mass spectrometry (MS) instruments in the United Kingdom, Japan, the United States, Europe, China, South Korea, and internationally. It develops and markets in-field screening solution for real-time monitoring used in various markets, such as water, pharmaceuticals, chemicals, academia, and food and beverage. The company offers MiD platform solutions for MS detection, including 4500 MiD; MiDas Automated Sampling interface that allows automated sampling, dilution, and injection for direct MS analysis; and MiD Protein ID, a miniaturised mass spectrometer, as well as sells consumables and spare parts. Its products are used in pharmaceuticals/biopharmaceuticals, food safety, environmental, and clinical applications. The company also provides support services and training programs, as well as sells its products through OEMs and distributors. Microsaic Systems plc was incorporated in 1998 and is headquartered in Woking, the United Kingdom.
URL
https://www.microsaic.com/
IPO date
Apr 11, 2011
Employees
22
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
492
-68.62%
1,568
72.87%
907
357.42%
Cost of revenue
193
1,402
4,371
Unusual Expense (Income)
NOPBT
299
166
(3,464)
NOPBT Margin
60.77%
10.58%
Operating Taxes
246
(268)
Tax Rate
148.49%
NOPAT
299
(80)
(3,196)
Net income
(2,597)
13.47%
(2,289)
-26.85%
(3,129)
31.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
200
5,083
BB yield
-5,989.06%
-38,248.13%
Debt
Debt current
8
53
71
Long-term debt
34
60
112
Deferred revenue
Other long-term liabilities
29
115
100
Net debt
(131)
(1,129)
(3,281)
Cash flow
Cash from operating activities
(1,058)
(2,133)
(1,603)
CAPEX
(2)
(208)
(334)
Cash from investing activities
48
(212)
(334)
Cash from financing activities
(59)
122
5,005
FCF
1,766
176
(3,741)
Balance
Cash
173
1,241
3,465
Long term investments
Excess cash
148
1,163
3,420
Stockholders' equity
(29,214)
(25,543)
(23,433)
Invested Capital
29,408
28,391
28,190
ROIC
1.03%
ROCE
154.12%
5.82%
EV
Common stock shares outstanding
10,178
10,119
8,860
Price
0.00
-78.00%
0.00
-25.00%
Market cap
3
-74.87%
13
810.04%
EV
(1,126)
(3,268)
EBITDA
585
447
(3,265)
EV/EBITDA
1.00
Interest
5
7
5
Interest/NOPBT
1.67%
4.23%